Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan

Shunsuke Komoto; Satoshi Motoya; Yuji Nishiwaki; Toshiyuki Matsui; Reiko Kunisaki; Katsuyoshi Matsuoka; Naoki Yoshimura; Takashi Kagaya; Makoto Naganuma; Nobuyuki Hida; Mamoru Watanabe; Toshifumi Hibi; Yasuo Suzuki; Soichiro Miura; Ryota Hokari; Japanese study group for pregnant women with IBD

doi:10.5217/ir.2016.14.2.139

Articles

Page Path: HOME > Intest Res > Volume 14(2); 2016 > Article

Original Article Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan: Shunsuke Komoto¹, Satoshi Motoya², Yuji Nishiwaki³, Toshiyuki Matsui⁴, Reiko Kunisaki⁵, Katsuyoshi Matsuoka⁶, Naoki Yoshimura⁷, Takashi Kagaya⁸, Makoto Naganuma⁹, Nobuyuki Hida¹⁰, Mamoru Watanabe⁶, Toshifumi Hibi¹¹, Yasuo Suzuki¹², Soichiro Miura¹³, Ryota Hokari¹, Japanese study group for pregnant women with IBD; Intestinal Research 2016;14(2):139-145.
DOI: https://doi.org/10.5217/ir.2016.14.2.139
Published online: April 27, 2016

¹Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

²IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan.

³Department of Environmental and Occupational Health, School of Medicine, Toho University, Tokyo, Japan.

⁴Department of Gastroenterology and Hepatology, Fukuoka University Chikushi Hospital, Fukuoka, Japan.

⁵IBD Center, Yokohama City University Medical Center, Yokohama, Japan.

⁶Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.

⁷Department of Internal Medicine, Division of IBD, Tokyo Yamate Medical Center, Tokyo, Japan.

⁸Department of gastroenterology, Kanazawa University Hospital, Ishikawa, Japan.

⁹Department of Gastroenterology and Hepatology, Keio University School of Medicine, Tokyo, Japan.

¹⁰Division of Internal Medicine, Department of IBD, Hyogo College of Medicine, Hyogo, Japan.

¹¹Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Tokyo, Japan.

¹²Department of Internal medicine, Sakura Medical Center, Toho University, Sakura, Japan.

¹³Department of Internal Medicine, National Defense Medical College, Saitama, Japan.

Correspondence to Ryota Hokari, Department of Internal Medicine, National Defense Medical College, 3-2, Namiki, Tokorozawa, Saitama 359-8513, Japan. Tel: +81-4-2995-1609, Fax: +81-4-2996-5201, ryota@ndmc.ac.jp

• Received: September 15, 2015 • Revised: February 12, 2016 • Accepted: February 15, 2016

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

prev next

7,065 Views
78 Download
25 Web of Science
23 Crossref
27 Scopus

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
REFERENCES

Abstract

Background/Aims
Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines.
Methods
This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines.
Results
Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037).
Conclusions
Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.
Keywords: Inflammatory bowel diseases; Anti tumor necrosis factor-alpha; Thiopurines; Pregnancy outcome

INTRODUCTION

Onset of IBD, namely CD and UC, typically occurs during young adulthood, thus affecting individuals during their reproductive years. Procreation is one of the most important events in an individual's life. Naturally, IBD patients and their families are concerned about the effects of disease activity and drug exposures on fertility, pregnancy outcomes, and the developing child.

Recently, it was reported that anti-tumor necrosis factor drugs (anti-TNF) do not affect pregnancy outcomes in mothers with IBD, or their infants (congenital malformations and immunosuppression).1 Further, recent data have not identified any increased risk of infections during the first year of life in children born to mothers who have received biologics, even in combination with immunomodulators (thiopurines).2 By contrast, the use of thiopurines in pregnancy and their effects on pregnancy outcomes are still controversial.3 A systematic review showed that thiopurine exposure in women with IBD was not associated with low birth weight (LBW) or congenital abnormalities, but that it was associated with preterm birth.4

A recent study indicated that a non-Caucasian ethnicity is a predictor of adverse pregnancy outcomes in women with IBD.5 However, pregnancy outcomes of IBD patients treated with anti-TNF and/or thiopurines have not been investigated in Asian countries. Reconfirmation of the results of previous reports from western countries is important, because the genetic backgrounds and environmental factors influencing IBD differ between Asian and Western countries.

We hypothesized that pregnancy outcomes of IBD patients in Asian countries were associated with exposure to anti-TNF and/or thiopurines. The aim of this study was to analyze the pregnancy outcomes of female Japanese IBD patients.

METHODS

1. Research Period and List of Collaborators

Between September 2008 and March 2014, a multicenter, cross-sectional study was conducted.

Members of the Japanese study group for pregnant women with IBD are as follows (shown in alphabetical order of affiliation): Toshiyuki Matsui, Kozue Tsurumi (Gastroenterology and Hepatology, Fukuoka University Chikushi Hospital), Shinji Tanaka, Yoshitaka Ueno (Department of Endoscopy, Hiroshima University Hospital), Shiro Nakamura, Nobuyuki Hida (IBD Center, Hyogo College of Medicine), Takashi Kagaya, Kazuya Kitamura (Department of gastroenterology, Kanazawa university), Makoto Naganuma (Department of Gastroenterology and Hepatology, Keio University School of Medicine), Hiroshi Nakase, Minoru Matsuura, Toshifumi Hibi (Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital), Takuya Yoshino (Department of Gastroenterology and Hepatology, Kyoto University Graduate School of Medicine), Motohiro Esaki (Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University), Shunsuke Komoto, Soichiro Miura, Ryota Hokari Chie Kurihara, Hirokazu Sato, Masaaki Higashiyama, Kenichi Yoshikawa, Chikako Watanabe (Department of Internal Medicine, National Defense Medical College), Kenji Watanabe (Department of Gastroenterology, Osaka City University Graduate School of Medicine), Kenji Fujimori (Third Department of Internal Medicine, Saitama Medical School Moroyama), Satoshi Motoya, Hiroki Tanaka (IBD Center, Sapporo Kosei General Hospital), Shunji Ishihara (Department of Internal Medicine II, Shimane University Faculty of Medicine), Reiko Kunisaki (IBD Center, Yokohama City University Medical Center), Akira Sugita (Department of Surgery, Yokohama Municipal Citizen's Hospital), Yasuo Suzuki (Department of Internal medicine, Sakura Medical Center, Toho University ), Katsuyoshi Matsuoka, Mamoru Watanabe (Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University), and Naoki Yoshimura (Department of Internal Medicine, Division of IBD, Tokyo Yamate Medical Center).

2. Research Method

A multicenter, cross-sectional study was conducted in Japan to investigate pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurine therapy. The medical records and birth outcomes of 72 pregnancies in 72 women were analyzed retrospectively in 18 collaborating hospitals, in which the treating gastroenterologists were members of the Research Committee for Inflammatory Bowel Disease. From the medical records, the following information was collected: type of disease (UC or CD), disease activity, and therapy. Each patient was given a questionnaire to answer. All data were anonymized and sent to an analysis center. Each patient completed a questionnaire, which gathered the following information regarding conception and pregnancy outcomes: smoking habits, alcohol consumption habits, and age at conception. Information was also requested regarding the outcome of the conceptions (live birth, spontaneous abortion, birth weight, and presence of congenital abnormalities). When women become pregnant in Japan, they receive a "notebook for mother and children" from regional health centers. Information regarding conception and the outcomes of the pregnancy was obtained from these notebooks. Information regarding pregnancy courses/outcomes and birth weight would be filled out by physicians or nurses in the notebooks. To identify the course and outcome of their pregnancies, patients referred to the notebooks. The study protocol was approved by the ethics committees at the National Defense Medical College (NDMC, No. 944) and was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from all subjects prior to participation.

3. Categorization of Subgroups

In the first analysis, pregnancies were classified into four groups depending on the drug exposure. Bio- IM-: pregnancies in women exposed to neither anti-TNF therapy or thiopurine therapy. Bio- IM+: pregnancies in women exposed to thiopurine therapy but not anti-TNF therapy. Bio+ IM-: pregnancies in women exposed to anti-TNF therapy but not thiopurine therapy. Bio+ IM+: pregnancies in women exposed to both anti-TNF therapy and thiopurine therapy.

In the second analysis, pregnancies were classified into 2 groups depending on the drug exposure. Bio-: pregnancies in women not exposed to anti-TNF therapy (alone or associated with thiopurines) Bio+: pregnancies in women exposed to anti-TNF therapy (alone or associated with thiopurines).

4. Disease Activity and Medical Therapy

Disease activity at the onset of pregnancy, medical therapy, and data regarding newborns were assessed retrospectively for each patient. The Harvey–Bradshaw index was calculated for CD activity and the partial Mayo score for UC activity.

5. Definition of Terms for Pregnancy Outcomes

LBW was defined as body weight less than 2500 g at birth. Preterm birth was defined as birth at less than 35 weeks gestational age. Congenital anomalies were defined as structural or functional defects present at birth.

6. Data Analysis and Statistical Methods

The prevalences of adverse outcomes were analyzed in this study, including spontaneous abortion, preterm birth, LBW, and congenital malformations. Outcomes of pregnancies in women with IBD among the four groups of treatment (Bio- IM-, Bio only, IM only, and Bio+ IM+), were compared. For statistical analyses, Fisher's exact method for categorical variables and the Kruskal Wallis test for continuous variables were assessed using STATA version 12 (STATA Corporation, College Station, Texas, USA).

RESULTS

1. Demographic Characteristics

Thirty-one pregnancies received neither anti-TNF and/or thiopurine therapy (Bio- IM-): 5 with CD, average age at delivery 34.4 [28–43] years; and 26 with UC, average age at delivery 31.5 [24–38] years. Twenty-four pregnancies received anti-TNF therapy only (Bio+): 24 with CD, average age at delivery 30.0 [20–36] years; and none with UC. Seven pregnancies received thiopurine therapy only (IM+): 4 with CD, average age at delivery 28.0 [24-35] years; and 3 with UC, average age at delivery 28.3 [19-35] years. Ten pregnancies received both anti-TNF and thiopurine therapy (Bio+ IM+): 6 with CD, average age at delivery 30.5 [25-34] years; and 4 with UC, average age at delivery 35.3 [31-39] years. Smoking was not observed in the Bio- IM- group and was more commonly observed in the Bio+ group (16.7%) and the IM+ group (28.6%). There was no difference in alcohol drinking habits among all groups. The above data regarding the patients' backgrounds are summarized in Table 1.

2. Therapy

Among 41 pregnancies in women with IBD who were exposed to anti-TNF treatment and/or thiopurines, 22 cases received infliximab, 2 cases received adalimumab, 6 cases received azathioprine (25-100 mg), 1 case received 6-mercaptopurine (60 mg), and 10 cases received a combination of infliximab and azathioprine. A combination of aminosalicylates plus anti-TNF therapy and/or thiopurines was used in 38 patients. A combination of oral prednisolone (5-30 mg) with infliximab and azathioprine was used in 2 cases. Of the 31 pregnancies in women with IBD who were not exposed to anti-TNF treatment or thiopurines, 28 received aminosalicylates. No patient received prednisolone treatment. Three patients received no therapy.

3. Disease Activity at Onset of Pregnancy

The mean Harvey–Bradshaw index at onset of pregnancy was 2.6 for the Bio- IM- group, 1.9 for Bio+ group, 3.6 for the IM+ group, and 4.2 for the Bio+ IM+ group. There were no significant differences between all 4 groups (P =0.067). Mean partial Mayo score at the onset of pregnancy was 0.9 in the Bio- IM- group, and 0.7 in IM+ and 2.2 in Bio+ IM+ groups. There were no significant differences between all 3 groups (P =0.111). The above data regarding the disease activity at onset of pregnancy are summarized in Table 2.

4. Pregnancy Outcomes

Between the 4 groups, Bio-IM-, Bio+IM-, Bio-IM+, and Bio+IM+, a statistically significant difference was observed in spontaneous abortion rates (Table 3, P =0.037). No significant differences were observed among the 4 groups concerning LBW, premature birth, birth weight, or congenital abnormality. Data of the pregnancy outcomes are summarized in Table 3.

Comparing the 2 groups Bio- and Bio+, a statistically significant difference was observed in spontaneous abortion rates between the 2 groups (Table 4, P =0.009). No significant differences were observed between the 2 groups concerning LBW, premature birth, birth weight, or congenital abnormality. Data of the pregnancy outcomes are summarized in Table 4.

DISCUSSION

Data on drug safety during pregnancy are largely restricted to the cumulative experience of patients and physicians and are often limited to case reports. Previous investigations of pregnancy outcomes in women with IBD are mainly limited to European populations. To our knowledge, this is the first Asian multicenter cross sectional study examining the outcomes of pregnancies in IBD patients treated with anti-TNF and/or thiopurine therapy.

Because pregnancy outcome is highly influenced by age,6 the ages of the patients were compared. There was no significant difference among 4 groups. In addition, disease activity has been associated with negative fetal outcomes in a number of reports.7 8 9 10 11 Meta-analysis has shown that disease activity at conception affects disease course during pregnancy.12 Thus, to determine the severity of disease in each patient, the Harvey–Bradshaw index was calculated for those with CD and the partial Mayo score was calculated for those with UC at the time of conception. There were no significant differences between all 4 groups of patients. LBW and the incidences of congenital malformations and childhood diseases did not increase in women who were exposed to anti-TNF or thiopurines during their pregnancies compared to those who were not exposed. The average gestational age of babies in the 4 groups, Bio-IM-, Bio+IM-, Bio-IM+, and Bio+IM+ were 30.0 weeks, 30.9 weeks, 30.7 weeks, and 31.9 weeks, respectively.

In Akbari's study, thiopurine exposure in women with IBD was associated with preterm birth.4 In our study, there was no increase in the incidence of preterm birth in pregnancies exposed to thiopurines. However, it is possible that we could not detect small differences because of the small sample size of this study. The incidences of LBW, preterm birth, and congenital malformation are 6.4%, 2.1%, and 1%-4% respectively in the normal population.13 In our analysis, the incidences of LBW, preterm birth, and congenital malformation in those who received either anti-TNF-alpha antibody or thiopurines were 17% (7/41), 7.3% (3/41), and 2.4% (1/41). On the other hand, the incidences of LBW, preterm birth, and congenital malformations in the group who had not received anti-TNF-alpha antibodies or thiopurines were 24% (7/29), 6.9% (2/29), and 6.5% (2/31). Incidences of LBW and preterm birth were higher in our study groups than in the general population regardless of the use of anti-TNF-alpha antibody or thiopurines, suggesting that IBD itself seems to be an independent risk factor for an abnormal outcome concerning LBW and preterm birth. Incidence of congenital malformation was comparable between the general population, those who received either anti-TNF-alpha antibodies or thiopurines, and those who did not receive anti-TNF-alpha antibody or thiopurines. Thus, we could not detect any proof of exposure to anti-TNF-alpha antibody or thiopurines being a risk factor for LBW, preterm birth, and congenital malformations. Our data support that medical maintenance treatment should be continued during pregnancy to avoid relapses.

In our analysis, spontaneous abortion occurred more commonly in the group exposed to anti-TNF-alpha antibodies. We observed significant differences when we divided the groups into 4 as well as into 2, as a comparison between patients who were treated with anti-TNF and who were not treated with anti-TNF. Another Japanese study reported that the incidences of spontaneous abortion (OR, 5.3; 95% CI, 1.1-25.0) were significantly higher in CD patients whose conceptions occurred after disease onset than in those who had conceived prior to disease onset. In that report, 3 patients had received anti-TNF-alpha antibody (infliximab).14 In our study, most patients treated with anti-TNF had CD (88%). Because the number of patients with UC who were treated with anti-TNF was small, we cannot conclude whether anti-TNF treatment was a risk factor for spontaneous abortion in the Japanese population. Although statistically nonsignificant, disease activity scores were higher in the anti-TNF- and thiopurine therapy-exposed groups. Whether this association is secondary to the use of anti-TNF or whether use of anti-TNF is only a marker for more severe disease is unclear. Johnson et al. reported outcomes of pregnancies in women with IBD treated with anti-TNF therapy from a Western country and showed that it may increase the risk of spontaneous abortion (exposed 5/34 vs. never exposed 3/55; OR, 2.99).15 In contrast, Schnitzler reported that the abortion rate in a TNF -exposed group vs. a non-exposed group was not significantly different (exposed 9/42 vs. non-exposed 12/78; OR, 1.5 [0.57 to 3.92]).2 In a systematic review and meta-analysis on the effects of anti-TNF-alpha antibodies on female patients with IBD, there was no increase in the occurrence of adverse pregnancy outcomes including spontaneous abortion in comparison with that reported in controls, except for the significant decrease in gestational age of newborns of drug-exposed mothers in 1 trial.16 Thus, the use of anti-TNF during pregnancy in IBD patients from Western countries appears to be acceptable. However, the pregnancy outcomes of patients with rheumatoid arthritis (another auto-immune disease treated with anti- TNF therapy) showed that the rate of spontaneous abortion was highest among patients exposed to anti-TNF at the time of conception (with methotrexate/leflunomide 33% and without methotrexate/leflunomide 24%). This compared with 10% spontaneous abortions in the control group. In that report, there was no significant increase in congenital malformations or premature birth.17 There was 1 case report of spontaneous abortion during use of ustekinumab, an anti-TNF agent, in women with psoriatic arthritis.18 Thus, concerning spontaneous abortion rates in IBD patients of Asian descent, no firm conclusions can be drawn about the safety of anti-TNF during pregnancy.

There are several limitations in our study. The number of patients was limited. Each drug exposure group included a mixture of CD and UC patients, and ratios were different in each group. Disease activity of each group was not matched.

In conclusion, exposure to anti-TNF treatment or thiopurines during pregnancy in IBD patients of Asian descent was not related to a higher incidence of adverse pregnancy outcomes in IBD patients except for spontaneous abortion. There is a possibility that the increased spontaneous abortion rate was associated with anti-TNF use. However, because the number of patients in our study is limited, a further large-scale study is necessary.

NOTES

Financial support: This study was supported in part by Health and Labour Sciences Research Grants for research on intractable diseases from the Ministry of Health, Labour and Welfare of Japan, and by grants from the National Defense Medical College.

Conflict of interest: None.

REFERENCES

1. Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med 2013;11:174PMID: 10.1186/1741-7015-11-174. PMID: 23902720.Article PubMed PMC PDF
2. Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011;17:1846–1854.PMID: 21830263.Article PubMed
3. Coelho J, Beaugerie L, Colombel JF, et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011;60:198–203.PMID: 21115547.Article PubMed
4. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis 2013;19:15–22.PMID: 22434610.Article PubMed
5. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133:1106–1112.PMID: 17764676.Article PubMed
6. Ziadeh S, Yahaya A. Pregnancy outcome at age 40 and older. Arch Gynecol Obstet 2001;265:30–33.PMID: 11327090.Article PubMed
7. Bush MC, Patel S, Lapinski RH, Stone JL. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004;15:237–241.PMID: 15280131.Article PubMed
8. Fedorkow DM, Persaud D, Nimrod CA. Inflammatory bowel disease: a controlled study of late pregnancy outcome. Am J Obstet Gynecol 1989;160:998–1001.PMID: 2712128.Article PubMed
9. Morales M, Berney T, Jenny A, Morel P, Extermann P. Crohn's disease as a risk factor for the outcome of pregnancy. Hepatogastroenterology 2000;47:1595–1598.PMID: 11149010.PubMed
10. Nørgård B, Hundborg HH, Jacobsen BA, Nielsen GL, Fonager K. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish cohort study. Am J Gastroenterol 2007;102:1947–1954.PMID: 17573787.Article PubMed
11. Reddy D, Murphy SJ, Kane SV, Present DH, Kornbluth AA. Relapses of inflammatory bowel disease during pregnancy: inhospital management and birth outcomes. Am J Gastroenterol 2008;103:1203–1209.PMID: 18422816.Article PubMed
12. Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:460–466.PMID: 23855477.Article PubMed PMC
13. Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 2007;56:830–837.PMID: 17185356.Article PubMed
14. Naganuma M, Kunisaki R, Yoshimura N, et al. Conception and pregnancy outcome in women with inflammatory bowel disease: a multicentre study from Japan. J Crohns Colitis 2011;5:317–323.PMID: 21683301.Article PubMed PDF
15. Johnson D, Jones K, Jimenez J, Mirrasoul N, Salas E, Chambers C. Pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in Pregnancy Project. Am J Gastroenterol 2009;104:S410.Article
16. Mozaffari S, Abdolghaffari AH, Nikfar S, Abdollahi M. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol 2015;34:445–459.PMID: 25378092.Article PubMed
17. Verstappen SM, King Y, Watson KD, Symmons DP, Hyrich KL. BSRBR Control Centre Consortium. BSR Biologics Register. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011;70:823–826.PMID: 21362710.Article PubMed PMC
18. Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012;6:105–107.PMID: 23329988.Article PubMed PMC

Table 1

Characteristics of Pregnant Patients With IBD Included in the Study

Variable	Bio- IM- ^a (n=31)	Bio only^b (n=24)	IM only^c (n=7)	Bio and IM^d (n=10)	P-value^e
UC/UC+CD	26/31 (83.9)	0/24 (0)	3/7 (42.9)	4/10 (40.0)	<0.001
Age	30.0	30.9	30.7	31.9	0.269
Duration of disease (median) (yr)	7.0	6.0	5.0	11.5	0.426
Smoking	0/31 (0)	4/24 (16.7)	2/7 (28.6)	1/10 (10.0)	0.022
Drinking	0/31 (0)	2/24 (8.3)	0/7 (0)	0/10 (0)	0.406

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 2

Disease Activity in Women With IBD at the Onset of Pregnancy

Variable	Bio- IM- ^a	Bio only^b	IM only^c	Bio and IM^d	P-value^e
HBI score (No. of CD)	2.6 (5)	1.9 (24)	3.6 (4)	4.2 (6)	0.067
Partial Mayo score (No. of UC)	0.9 (26)	ND	0.7 (3)	2.2 (4)	0.111

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables.

Bio, biologics; IM, immunomodulator; HBI, Harvey-Bradshaw Index; ND, not done.

Table 3

Comparison of Pregnancy Outcomes in Patients With IBD Among Four Different Treatment Groups

Variable	Bio- IM- ^a (n=31)	Bio only^b (n=24)	IM only^c (n=7)	Bio and IM^d (n=10)	P-value^e
Premature birth	2/29 (6.9)	1/17 (5.9)	1/7 (14.3)	1/8 (12.5)	0.618
Low birth weight	7/29 (24.1)	4/17 (23.5)	1/7 (14.3)	2/8 (25.0)	1.000
Birth weight (median) (g)	2920	2844	2700	2738	0.886
Congenital anomaly	2/31 (6.5)	0/24 (0)	0/7 (0)	1/10 (10.0)	0.457
Spontaneous abortion	0/31 (0)	4/24 (16.7)	0/7 (0)	2/10 (20.0)	0.037

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 4

Comparison of Pregnancy Outcomes in Patients With IBD Between the Group that Received Biologics Treatments and the Group Who Did not Receive Biologics Treatments

Variable	TNF (-) (n=38)	TNF (+) (n=34)	P-value^a
UC/UC+CD	29/38 (76.3)	4/34 (11.8)	<0.001
Premature birth	3/36 (8.3)	2/25 (8.0)	1.000
Low birth weight	8/36 (22.2)	6/25 (24.0)	1.000
Birth weight (median) (g)	2890	2844	0.655
Congenital anomaly	2/38 (5.3)	1/34 (2.9)	1.000
Spontaneous abortion	0/38 (0)	6/34 (17.7)	0.009

Values are presented as n (%).

^aFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

TNF, tumor necrosis factor.

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología.2024; 31(3): 290. CrossRef
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review
Wei Huang, Xinxing Zhang, Li Zhang, Xiaosong Dai, Heping Chen, Qin Xie
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología (English Edition).2024; 31(3): 290. CrossRef
Ulcerative Colitis in Pregnancy: A Japanese Multicenter Cohort Study Focusing on Their Mutual Influence
Yuichi Shimodate, Akiko Shiotani, Ken-ichi Tarumi, Hiroshi Matsumoto, Osamu Handa, Noriaki Tomioka, Naoyuki Nishimura, Kazuhiro Matsueda, Hirokazu Mouri, Motowo Mizuno
Internal Medicine.2024;[Epub] CrossRef
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
Raed Alhusayen, Serena Dienes, Megan Lam, Afsaneh Alavi, Ali Alikhan, Maria Aleshin, Emad Bahashwan, Steve Daveluy, Noah Goldfarb, Amit Garg, Wayne Gulliver, Tarannum Jaleel, Alexa B. Kimball, Mark G. Kirchhof, Joslyn Kirby, Joi Lenczowski, Hadar Lev-Tov,
Journal of the American Academy of Dermatology.2024;[Epub] CrossRef
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy
Nahla A. Azzam, Abdulelah Almutairdi, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baw
Saudi Journal of Gastroenterology.2023;[Epub] CrossRef
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Clinical Gastroenterology and Hepatology.2022; 20(1): 74. CrossRef
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Se
Rheumatology.2022;[Epub] CrossRef
Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
Current Pharmaceutical Design.2021; 27(19): 2317. CrossRef
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Anja Geldhof, Jennifer Slater, Michael Clark, Urmila Chandran, Danielle Coppola
Drug Safety.2020; 43(2): 147. CrossRef
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
The Korean Journal of Internal Medicine.2020; 35(1): 41. CrossRef
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Journal of Rheumatic Diseases.2020; 27(1): 4. CrossRef
Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies
Nicole W Tsao, Nevena Rebic, Larry D Lynd, Mary A De Vera
Rheumatology.2020; 59(8): 1808. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef
Pregnancy and Neuromyelitis Optica Spectrum Disorder – Reciprocal Effects and Practical Recommendations: A Systematic Review
Rohan D'Souza, Danielle Wuebbolt, Katarina Andrejevic, Rizwana Ashraf, Vanessa Nguyen, Nusrat Zaffar, Dalia Rotstein, Ahraaz Wyne
Frontiers in Neurology.2020;[Epub] CrossRef
Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: A Retrospective Evaluation
Ayumi Ito, Bunei Iizuka, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
Internal Medicine.2018; 57(2): 159. CrossRef
The use of biologics and small molecules in pregnant patients with rheumatic diseases
Maria Gerosa, Lorenza Maria Argolini, Carolina Artusi, Cecilia Beatrice Chighizola
Expert Review of Clinical Pharmacology.2018; 11(10): 987. CrossRef
Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280. CrossRef
Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis
Begoña Gonzalez-Suarez, Shreyashee Sengupta, Alan C Moss
World Journal of Gastroenterology.2017; 23(45): 8082. CrossRef
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
Intestinal Research.2017; 15(1): 90. CrossRef
Concerns in pregnancy and childbirth of women with inflammatory bowel disease
Sung-Ae Jung
Intestinal Research.2016; 14(2): 107. CrossRef
Common Adverse Effects of Anti-TNF Agents on Gestation
Zacharias Fasoulakis, Panagiotis Antsaklis, Nikolaos Galanopoulos, Emmanuel Kontomanolis
Obstetrics and Gynecology International.2016; 2016: 1. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan

Intest Res. 2016;14(2):139-145. Published online April 27, 2016

DOI: https://doi.org/10.5217/ir.2016.14.2.139

XML Download

Related articles

Malnutrition and inflammation status in nonobese patients with inflammatory bowel disease are associated with nonalcoholic fatty liver disease: a retrospective study

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan

Table 1

Characteristics of Pregnant Patients With IBD Included in the Study

Variable	Bio- IM- ^a (n=31)	Bio only^b (n=24)	IM only^c (n=7)	Bio and IM^d (n=10)	P-value^e
UC/UC+CD	26/31 (83.9)	0/24 (0)	3/7 (42.9)	4/10 (40.0)	<0.001
Age	30.0	30.9	30.7	31.9	0.269
Duration of disease (median) (yr)	7.0	6.0	5.0	11.5	0.426
Smoking	0/31 (0)	4/24 (16.7)	2/7 (28.6)	1/10 (10.0)	0.022
Drinking	0/31 (0)	2/24 (8.3)	0/7 (0)	0/10 (0)	0.406

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 2

Disease Activity in Women With IBD at the Onset of Pregnancy

Variable	Bio- IM- ^a	Bio only^b	IM only^c	Bio and IM^d	P-value^e
HBI score (No. of CD)	2.6 (5)	1.9 (24)	3.6 (4)	4.2 (6)	0.067
Partial Mayo score (No. of UC)	0.9 (26)	ND	0.7 (3)	2.2 (4)	0.111

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables.

Bio, biologics; IM, immunomodulator; HBI, Harvey-Bradshaw Index; ND, not done.

Table 3

Comparison of Pregnancy Outcomes in Patients With IBD Among Four Different Treatment Groups

Variable	Bio- IM- ^a (n=31)	Bio only^b (n=24)	IM only^c (n=7)	Bio and IM^d (n=10)	P-value^e
Premature birth	2/29 (6.9)	1/17 (5.9)	1/7 (14.3)	1/8 (12.5)	0.618
Low birth weight	7/29 (24.1)	4/17 (23.5)	1/7 (14.3)	2/8 (25.0)	1.000
Birth weight (median) (g)	2920	2844	2700	2738	0.886
Congenital anomaly	2/31 (6.5)	0/24 (0)	0/7 (0)	1/10 (10.0)	0.457
Spontaneous abortion	0/31 (0)	4/24 (16.7)	0/7 (0)	2/10 (20.0)	0.037

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 4

Comparison of Pregnancy Outcomes in Patients With IBD Between the Group that Received Biologics Treatments and the Group Who Did not Receive Biologics Treatments

Variable	TNF (-) (n=38)	TNF (+) (n=34)	P-value^a
UC/UC+CD	29/38 (76.3)	4/34 (11.8)	<0.001
Premature birth	3/36 (8.3)	2/25 (8.0)	1.000
Low birth weight	8/36 (22.2)	6/25 (24.0)	1.000
Birth weight (median) (g)	2890	2844	0.655
Congenital anomaly	2/38 (5.3)	1/34 (2.9)	1.000
Spontaneous abortion	0/38 (0)	6/34 (17.7)	0.009

Values are presented as n (%).

^aFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

TNF, tumor necrosis factor.

Table 1 Characteristics of Pregnant Patients With IBD Included in the Study

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 2 Disease Activity in Women With IBD at the Onset of Pregnancy

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables.

Bio, biologics; IM, immunomodulator; HBI, Harvey-Bradshaw Index; ND, not done.

Table 3 Comparison of Pregnancy Outcomes in Patients With IBD Among Four Different Treatment Groups

Values are presented as n (%).

^aPregnancies received neither anti-TNF or thiopurine therapy.

^bPregnancies received anti-TNF therapy only.

^cPregnancies received thiopurine therapy only.

^dPregnancies received both anti-TNF and thiopurine therapy.

^eFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.

Bio, biologics; IM, immunomodulator.

Table 4 Comparison of Pregnancy Outcomes in Patients With IBD Between the Group that Received Biologics Treatments and the Group Who Did not Receive Biologics Treatments

Values are presented as n (%).

^aFisher's exact method for categorical variables and Kruskal Wallis test for continuous variables.